• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Alexion’s new drug hits FDA snag

Alexion’s new drug hits FDA snag

September 4, 2015
CenterWatch Staff

Cheshire, Conn.-based Alexion Pharmaceuticals, striving to expand its stable of products beyond the world’s most expensive drug, will need to wait a little longer for the U.S. launch of a second treatment because the FDA wants extra time to look over its application.

Alexion’s Kanuma (sebelipase alfa) was scheduled for a final decision next week under the FDA’s priority review program, but the company said that the agency has added another 90 days to the process in order to examine requested additional information on the drug’s manufacturing. The three-month delay almost negates the benefit of the priority tag, which shortens the usual 10-month review process to six months.

Kanuma, a treatment for the ultra-rare lysosomal acid lipase deficiency (LAL-D), was the focal point of Alexion’s $8.4 billion acquisition of Synageva earlier this year. Alongside the Alexion-invented Strensiq (asfotase alfa), scheduled for FDA approval later this year, Kanuma is a key to the biotech’s planned growth. The company made its reputation with Soliris, a rare disease treatment that costs more than $500,000 annually, and Alexion now is looking to build a stable of additional therapies.

Strensiq and Kanuma won tandem European approvals this week, and Alexion plans to initiate a nation-by-nation rollout in the next few months. The company hasn’t divulged pricing information on the two new drugs, but Barclays analyst Geoff Meacham penned a note to investors indicating that Alexion likely will charge roughly $375,000 annually for each.

LAL-D is caused by a genetic mutation that results in a loss of LAL enzymes, contributing to dangerous buildups of cholesterol and triglycerides that can cause severe damage to the liver. Kanuma, which is an enzyme-replacement therapy, works by counteracting that process.

Upcoming Events

  • 17May

    Three Data Trends to Consider Now When Developing Your Decentralized Clinical Trial Strategy

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing